Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olmesartan Medoxomil/Amlodipine vs Higher-dose Olmesartan in Essential Hypertension
jRCT2080221543Phase 3
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in essential hypertension comparing Olmesartan medoxomil/amlodipine 20/5 mg with Olmesartan medoxomil 40 mg (2 arms).
02
Drugs
olmesartanamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on jRCT2080221543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221543.